Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Holding AMGN?
Track your performance easily
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$249.70 - $346.85
Previous Close$332.8
Volume1.37M
Average Volume (3M)2.07M
Market Cap
$178.82B
Enterprise Value$232.17B
Total Cash (Recent Filing)$9.30B
Total Debt (Recent Filing)$62.65B
Price to Earnings (P/E)57.8
Beta0.50
Next Earnings
Oct 29, 2024EPS Estimate
$5.14Last Dividend Ex-Date
Aug 16, 2024Dividend Yield2.65%
Share Statistics
EPS (TTM)5.80
Shares Outstanding537,329,220
10 Day Avg. Volume1,800,425
30 Day Avg. Volume2,067,965
Standard Deviation0.07
R-Squared0.19
Alpha0.00538
Financial Highlights & Ratios
Price to Book (P/B)30.17
Price to Sales (P/S)5.82
Price to Cash Flow (P/CF)18.20
P/FCF Ratio15.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.51
Enterprise Value/Gross Profit11.76
Enterprise Value/Ebitda19.48
Forecast
1Y Price Target
$339.31Price Target Upside1.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Amgen News
Bulls Say, Bears Say
Bulls Say
New Market OpportunitiesTepezza is expected to add another $1bn in annual sales over the balance of the decade.
Pipeline PotentialOptimism is high for upcoming Ph3 data for Uplizna in myasthenia gravis following a positive readout in IgG4-related disease.
Product Sales GrowthProduct sales growth was driven by 26% volume growth.
Bears Say
CompetitionCompetitor Viridian disclosed veligrotug phase 3 results showing high-level efficacy in line with Tepezza but with less infusion burden and potentially a better safety profile.
Financial PerformanceMisses from the company's base business (Enbrel -6% vs. cons and Repatha -1% vs. cons), offset by some strength from the growth portfolio.
Growth PressureThere is growth pressure driven by biosimilar competition for Prolia/Xgeva, which contribute to ~20% of AMGN revenues.
---
Ownership Overview
1.08% Insiders
23.10% Mutual Funds
44.00% Other Institutional Investors
31.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $249.70 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Oct 29, 2024 which is in 40 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 06, 2024. The company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $4.985 by -$0.015.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.65%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $5.14.
How many shares outstanding does Amgen have?
Amgen has 537,329,200 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.97 in its last earnings report, missing expectations of $4.985. Following the earnings report the stock price went down -5.002%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 5B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$339.31 (1.92% Upside)
$339.31 (1.92% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 231.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.48%
12-Months-Change
Fundamentals
Return on Equity
49.27%
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q2 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$339.31
▲(1.92% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
26/30 ratings generated profit
1 Year Average Return
+17.25%
assigned a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +17.25% per trade.
---